Kedrion S.p.A.

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Kedrion S.p.A. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 3 currently recruiting 3 completed later-stage tilt upper quartile by trial count

Kedrion S.p.A.: 8 sponsored US clinical trials, 3 recruiting.

Kedrion S.p.A. sponsors 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 7 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Immunodeficiency Disease, with 1 trials.

Upper-quartile sponsor footprint

Kedrion S.p.A. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 3

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06752356
RECRUITING Phase 3

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

NCT06963216
RECRUITING Phase 3

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000
ACTIVE NOT RECRUITING Phase 3

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

NCT04944979
COMPLETED Phase 3

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

NCT03961009
TERMINATED Phase 4

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

NCT01531803
COMPLETED Phase 2

Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients

NCT01554956
COMPLETED Phase 3

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT01581593

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 6
Phase 4 1

Therapeutic Areas

Primary Immunodeficiency Disease 1
Chronic Primary Immune Thrombocytopenia (ITP) 1
Acquired Factor X Deficiency 1
Chronic Inflammatory Demyelinating Polyneuropathy 1

Where Kedrion S.p.A. enrollment is open (later-stage tilt)

3 recruiting of 8 indexed (38% open); 3 completed (38%).

Phase mix: 7 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Primary Immunodeficiency Disease (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kedrion S.p.A.: open-pipeline peers nationwide

Peers matched on 8 registered trials and 38% open enrollment, not the therapeutic-area sidebar.

Kedrion S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8.088.1 0%10%20%30%40% Total trials Recruiting share Kedrion S.p.A.AB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)American Thrombosis and Hemostasis NetworkAskBioAthletic Greens InternationalBanner Health
Kedrion S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kedrion S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 38% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kedrion S.p.A. page

8 registered trials is a research-attention snapshot, not an endorsement of Kedrion S.p.A. or any single study.

  • 3 of Kedrion S.p.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Primary Immunodeficiency Disease is the condition Kedrion S.p.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Immunodeficiency Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Kedrion S.p.A. pipeline card: 8 registered trials from official public datasets.Report a data error.